Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2000
11/30/2000WO2000071104A2 Use of bisphosphonic acids for treating angiogenesis
11/30/2000WO2000071103A2 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
11/30/2000WO2000071102A2 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
11/30/2000WO2000071101A2 Methods and compounds for inhibiting amyloid deposits
11/30/2000WO2000071100A1 Device and method for increasing the transdermal permeation of medicaments
11/30/2000WO2000071099A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
11/30/2000WO2000071097A1 Composition containing ascorbic acid salt
11/30/2000WO2000071095A2 Release of poorly soluble agents
11/30/2000WO2000071094A1 Ascorbic acid derivative composition for increasing cell renewal rate
11/30/2000WO2000071093A1 Niacinamide compositions with reduced tack
11/30/2000WO2000071092A1 Skin whitener
11/30/2000WO2000071079A2 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
11/30/2000WO2000071078A2 Composition designed for implementing an antitumoral or antiviral treatment in a mammal
11/30/2000WO2000070964A1 Method for increasing propionate in the gastro-intestinal tract
11/30/2000WO2000070949A1 Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
11/30/2000WO2000054745A3 Devices and methods for pain management
11/30/2000WO2000049993A3 Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
11/30/2000WO2000047559A3 5-ht1f agonists
11/30/2000WO2000046199A3 Indole derivatives as anti-inflammation agents
11/30/2000WO2000044379A3 Methods for restoring and/or enhancing accommodation in pseudo phakia
11/30/2000WO2000044360A3 Drugs for treatment of psychiatric and brain disorders
11/30/2000WO2000043525A3 Metalloproteinase-disintegrin family members: svph dnas and polypeptides
11/30/2000WO2000043408A3 Steroid sulfatase inhibitors and methods for making and using the same
11/30/2000WO2000043014A3 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
11/30/2000WO2000042995A3 Use of anticonvulsant derivatives for treating transformed migraine
11/30/2000WO2000042993A3 Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
11/30/2000WO2000042989A3 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
11/30/2000WO2000042201A3 Human peptidases
11/30/2000WO2000041725A3 Therapeutic compositions for metabolic bone disorders or bone metastases
11/30/2000WO2000041694A3 Compositions having improved stability
11/30/2000WO2000041693A3 Compositions having improved delivery of actives
11/30/2000WO2000041692A3 Compositions having improved stability
11/30/2000WO2000041687A3 Composition and methods for administration of water-insoluble paclitaxel derivatives
11/30/2000WO2000041547A3 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
11/30/2000WO2000040605A3 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
11/30/2000WO2000040269A3 Pharmaceutical compositions for treatment of diseased tissues
11/30/2000WO2000040241A3 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
11/30/2000WO2000038716A9 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
11/30/2000WO2000035434A3 Compositions and methods for the treatment of anorectal disorders
11/30/2000WO2000034481A3 DRUG TARGETS IN $i(CANDIDA ALBICANS)
11/30/2000WO2000034338A3 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/30/2000WO2000032598A9 Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity
11/30/2000WO2000032583A9 Antitumor dibenzofluorene derivatives
11/30/2000WO2000028027A3 Corticosteroid synthesis-associated genes
11/30/2000WO2000028019A3 Antisense oligomer
11/30/2000WO2000027363A9 Aerosols comprising nanoparticle drugs
11/30/2000WO2000025829A3 Radiodense compositions
11/30/2000WO2000024391A3 Conductance of improperly folded proteins through the secretory pathway
11/30/2000WO2000021572A3 Hydrogels and water soluble polymeric carriers for drug delivery
11/30/2000WO2000021511A3 Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
11/30/2000WO2000018918A3 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
11/30/2000WO2000010554A3 Methods and compositions employing optically pure s(+) vigabatrin
11/30/2000DE19924872A1 Antikonvulsiv wirkende Pyrazolo[3,4-d][1,2,3]triazine und Verfahren zu ihrer Herstellung Anticonvulsant acting pyrazolo [3,4-d] [1,2,3] triazines and process for their preparation
11/30/2000DE19924819A1 Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren) Substituted Phenylcyclohexancarbonsäurebenzylamid (adenosine uptake inhibitors)
11/30/2000DE19924818A1 Substituierte Phenylcyclohexancarbonsäureamide Substituted Phenylcyclohexancarbonsäureamide
11/30/2000DE19924525A1 Composition containing topical glucocorticoid and detumescent, useful for treating e.g. hayfever and sinusitis
11/30/2000DE19923961A1 Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
11/30/2000DE19923838A1 Use of flavonoids for photostabilizing sorbate-containing compositions
11/30/2000DE19923551A1 Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht A pharmaceutical preparation containing the active substance diamorphine and its use in a method for the treatment of opiate addiction
11/30/2000CA2698347A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
11/30/2000CA2684016A1 Methods and compounds for inhibiting amyloid deposits
11/30/2000CA2384287A1 Methods of treating proliferative disorders
11/30/2000CA2382751A1 Inhibitors of factor xa
11/30/2000CA2381441A1 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
11/30/2000CA2375543A1 Salts of cis-¬4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylate|
11/30/2000CA2375072A1 Prodrug activation using catalytic antibodies
11/30/2000CA2375066A1 Antibiotic prodrugs
11/30/2000CA2375032A1 Cd4-independent hiv envelope proteins as vaccines and therapeutics
11/30/2000CA2374947A1 Inhibitors of factor xa
11/30/2000CA2374941A1 Composition designed for implementing an antitumoral or antiviral treatment in a mammal
11/30/2000CA2374926A1 Thiazoloderivatives and pharmaceutical compositions containing them
11/30/2000CA2374918A1 Identification of novel mechanisms of drug resistance
11/30/2000CA2374915A1 Substituted imidazothiazoles as antidepressant agents
11/30/2000CA2374820A1 Inhibitors of factor xa
11/30/2000CA2374793A1 Inhibitors of factor xa
11/30/2000CA2374788A1 Inhibitors of factor xa
11/30/2000CA2374714A1 Purine derivatives, preparation method and pharmaceutical compositions containing same
11/30/2000CA2374677A1 Pharmaceutical compositions comprising desmethyselegiline for the treatment of drug withdrawal
11/30/2000CA2374674A1 Tumor necrosis factor receptor 5
11/30/2000CA2374668A1 New pharmaceutical combinations for nos inhibitors
11/30/2000CA2374650A1 Inhibitors of factor xa
11/30/2000CA2374646A1 Inhibitors of factor xa
11/30/2000CA2374641A1 Inhibitors of factor xa
11/30/2000CA2374540A1 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
11/30/2000CA2374507A1 Assay for the detection of paclitaxel resistant cells in human tumors
11/30/2000CA2374499A1 Antisense to c-myc for treatment of polycystic kidney disease
11/30/2000CA2374421A1 High specificity hairpin antisense oligonucleotides
11/30/2000CA2374225A1 Naphthalene ureas as glucose uptake enhancers
11/30/2000CA2374051A1 Release of poorly soluble agents
11/30/2000CA2374049A1 Use of bisphosphonic acids for treating angiogenesis
11/30/2000CA2374021A1 Methods for regulating protein conformation using molecular chaperones
11/30/2000CA2373994A1 Emulsion vehicle for poorly soluble drugs
11/30/2000CA2373992A1 Medicinal compositions containing anti-fas antibody
11/30/2000CA2373967A1 Mag expression promoters
11/30/2000CA2373793A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents
11/30/2000CA2373789A1 Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
11/30/2000CA2373783A1 Method and apparatus for loading a container with a product
11/30/2000CA2373751A1 Isoflavonoid methylation enzyme
11/30/2000CA2373748A1 Use of chimeric mutational vectors to change endogenous nucleotide sequences in solid tissues
11/30/2000CA2373693A1 Seven transmembrane receptor genes
1 ... 6200 6201 6202 6203 6204 6205 6206 6207 6208 6209 6210 6211 6212 6213 6214 6215 6216 6217 6218 6219 6220 ... 7860